• Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors
• NBE-Therapeutics’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform
• NBE-Therapeutics’ will remain at its…